Pro Football Hall of Famer Dan Marino speaks candidly about his 2007 MASH diagnosis and why he is eager to share his health story. Through a new partnership with Novo Nordisk, he hopes to raise greater awareness about the importance of fatty liver disease management.
Novo Nordisk A/S shareholders who purchased their securities between May 7, 2025, and July 28, 2025, are advised by Rosen Law Firm to consider legal action. With the lead plaintiff deadline set for September 30, 2025, investors are encouraged to act promptly to secure potential compensation.
Novo Nordisk, the Danish pharmaceutical company known for Ozempic, is suspending new hires as it struggles to meet its lofty sales expectations. The move highlights the broader financial pressures the company has faced in recent months.
Geo Capital Gestora de Recursos Ltd decreased its holdings in Novo Nordisk A/S by 8.2% in the first quarter, selling 5,826 shares. The fund retains 65,515 shares, demonstrating continued confidence in the pharmaceutical company despite the latest change.
Viking Therapeutics’ experimental pill helped patients lose 12.2 % of their body weight in just 13 weeks—better than Eli Lilly’s latest effort but still shy of Novo Nordisk’s own results. Yet it was Novo Nordisk’s shares that “popped,” underscoring how the race for obesity drugs can move markets in unexpected ways.
